Cadrenal Therapeutics
CVKD
19 hedge funds and large institutions have $380K invested in Cadrenal Therapeutics in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 7 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0.07% more ownership
Funds ownership: 3.89% → 3.96% (+0.07%)
5% less funds holding
Funds holding: 20 → 19 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
17% less capital invested
Capital invested by funds: $460K → $380K (-$80.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$138K |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$23.4K |
| 3 |
CA
CoreCap Advisors
Southfield,
Michigan
|
+$6.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.27K |
| 5 |
GBT
Grove Bank & Trust
Miami,
Florida
|
+$4.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$31.9K |
| 2 |
BlackRock
New York
|
-$28.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$12.4K |
| 4 |
CCA
Cygnus Capital Advisors
Atlanta,
Georgia
|
-$8K |
| 5 |
DWP
Destiny Wealth Partners
Tavares,
Florida
|
-$1.02K |
CVKD Hedge Fund Activity: Q2 2026 in Review
19 of the 8,324 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q2 2026, worth a combined $380K — down 17% from $460K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CVKD and 6 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $138K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $31.9K sold.
- 19 institutional investors held Cadrenal Therapeutics (CVKD) as of Q2 2026, down from 20 in Q1 2026.
- Funds reported $380K of Cadrenal Therapeutics stock for Q2 2026, down 17% quarter-over-quarter.
- 6 funds opened new Cadrenal Therapeutics positions in Q2 2026 and 7 closed out, a net change of -1 holder.
- The largest Cadrenal Therapeutics buyer in Q2 2026 was HRT Financial, an estimated $138K added.
- The largest Cadrenal Therapeutics seller in Q2 2026 was JP Morgan Chase, an estimated $31.9K sold.
Based on aggregated 13F filings for Q2 2026.